Shopping Cart
- Remove All
Your shopping cart is currently empty
SEP-363856 is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,520 | 1-2 weeks | |
| 50 mg | $1,980 | 1-2 weeks | |
| 100 mg | $2,500 | 1-2 weeks |
| Description | SEP-363856 is an agent of orally active and CNS active psychotropic with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects, has the potential to treatment of schizophrenia. |
| Targets&IC50 | 5-HT7 receptor:6.7 μM (EC50), 5-HT1B receptor:15.6 μM (EC50), 5-HT2A receptor:10 μM (EC50), TAAR1:0.140 μM (EC50), 5-HT1D receptor:0.262 μM (EC50), 5-HT1A receptor:2.3 μM (EC50), 5-HT2C receptor:30 μM (EC50) |
| In vitro | SEP-856 (10μM) specifically inhibits α2A, α2B, D2, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C and 5-HT7> 50% receptor. |
| In vivo | SEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active. SEP-856 exhibits a behavioral signature similar to known antipsychotic drugs.PCP-induced hyperactivitysignificantly reduced by SEP-856 (0.3, 1 and 10 mg/kg, orally once) . Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time. |
| Synonyms | SEP-856 |
| Molecular Weight | 183.27 |
| Formula | C9H13NOS |
| Cas No. | 1310426-33-5 |
| Relative Density. | 1.123 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.